Show simple item record

dc.contributor.authorDegryse, Sandrine
dc.contributor.authorCools, Jan
dc.date.accessioned2015-09-01T16:58:59Z
dc.date.available2015-09-01T16:58:59Z
dc.date.issued2015-07-26
dc.identifier.citationJournal of Hematology & Oncology. 2015 Jul 26;8(1):91
dc.identifier.urihttp://dx.doi.org/10.1186/s13045-015-0192-7
dc.identifier.urihttp://hdl.handle.net/10724/31696
dc.description.abstractAbstract Recent studies of acute lymphoblastic leukemia have identified activating mutations in components of the interleukin-7 receptor complex (IL7R, JAK1, and JAK3). It will be of interest to investigate both JAK1 and JAK3 kinase inhibitors as targeted agents for these leukemias.
dc.titleJAK kinase inhibitors for the treatment of acute lymphoblastic leukemia
dc.typeJournal Article
dc.date.updated2015-07-29T18:13:11Z
dc.language.rfc3066en
dc.rights.holderDegryse and Cools.


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record